MedTrace Logo

Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis

NCT04275232 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-11-22

No results posted yet for this study

Summary

Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request from the Sponsor-Investigator to Canadian Blood Services, as approved by Health Canada.

Conditions

  • Ligneous Conjunctivitis, Left Eye

Interventions

BIOLOGICAL

Allogenic plasma aliquots, a source of plasminogen

Plasma eye drops, a source of plasminogen

Sponsors & Collaborators

  • Canadian Blood Services

    collaborator OTHER

  • Dorothy Bautista, MD

    lead OTHER

Principal Investigators

  • Dorothy V Bautista, MD · Memorial University of Newfoundland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04275232 on ClinicalTrials.gov